Lapsed Dec 1, 2023 on the fee record · High confidence
20-year base term ends Jun 24, 2033
Second maintenance fee unpaid; grace period ended.
Held by Vyne Therapeutics Inc.
Filed Jun 24, 2014 as application 14/312,942 · Granted Dec 1, 2015
Base term, 20 years from filing
Today
Lapsed Dec 1, 2023
2013
2033
Clock starts
Jun 24, 2013
Jun 24, 2013
No longer in force
Dec 1, 2023
Dec 1, 2023
Granted
Dec 1, 2015
Dec 1, 2015
Term would have run to
Jun 24, 2033
Jun 24, 2033
base term
after the term ends
fee events
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,906,951, to Jun 24, 2033. The term already ends on or before that date, so the cap shortened nothing.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
15
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
Its term would have run to Jun 24, 2033: its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jun 24, 2013, when application 13/925,509, the earliest non-provisional in its chain, was filed (this one was filed Jun 24, 2014) | Jun 24, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,906,951) | resolves to Jun 24, 2033, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | lapsed Dec 1, 2023 | High confidence |
| Computed term end | The steps above, in order | Dec 1, 2023 | High confidence |
This family
| US 8,906,951 | In force Jun 2033 | Jun 2033 |
| US 9,198,898 | this patent Dec 2023 | Dec 2023 |
| Application PCT/US2014/043811 | PCT application no patent term | no patent term |
| US 9,381,188 | Lapsed on the fee record Jul 2024 | Jul 2024 |
| US 9,486,439 | Lapsed on the fee record Nov 2024 | Nov 2024 |
| US 9,474,741 | Lapsed on the fee record Oct 2024 | Oct 2024 |
| US 9,737,507 | Lapsed on the fee record Aug 2025 | Aug 2025 |
| US 9,737,508 | Lapsed on the fee record Aug 2025 | Aug 2025 |
8 of 15 applications in this family shown, earliest filings first. Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Aug 22, 2014 Reel 33594, frame 99 | Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W. | Tigercat Pharma, Inc. | Assignment of Assignor's Interest |
| Jul 6, 2016 Reel 39197, frame 765 | Tigercat Pharma, Inc. | Menlo Therapeutics Inc. | Change of Name |
| May 5, 2017 Reel 42258, frame 517 | Zhang, Xiaoming; Schnipper, Edward F.; Perlman, Andrew J.; Larrick, James W. | Tigercat Pharma, Inc. | Assignment of Assignor's Interest |
| Mar 9, 2020 Reel 52130, frame 980 | Menlo Therapeutics Inc. | Perceptive Credit Holdings II, LP | Patent Security Agreement |
| Dec 1, 2020 Reel 54558, frame 437 | Menlo Therapeutics Inc. | Vyne Therapeutics Inc. | Change of Name |
| Sep 20, 2021 Reel 57531, frame 986 | Perceptive Credit Holdings II, LP | Vyne Therapeutics Inc. (F/K/A Menlo Therapeutics Inc. and Successor-in-Interest to Vyne Pharmaceuticals Ltd., F/K/A Foamix Pharmaceuticals Ltd.) | Release of Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,906,951, ends no earlier than this term, so it caps nothing.
Citations
46
later US patents cite this one
That is top 10% of utility patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.